Toripalimab is a PD-1 antibody that inhibits the immune escape mechanism of melanoma cells by targeting the immune checkpoint PD-1, a membrane surface receptor that regulates immune response homeostasis and prevents over-activated immune cells from attacking normal tissue. The gene discussed is PDCD1; the disease is melanoma.